The rationale behind combination therapy relates to the fact that when two different classes of agents are combined, they may provide complementary, additive, or synergistic antihypertensive effects through different mechanisms. Lower doses of two drugs, which provide blood pressure reduction similar to higher doses of one drug, may enhance tolerability and improve compliance. Investigative efforts have been undertaken to explore fixed-dose combinations of drugs that do not include diuretics. The first nondiuretic fixed-dose combinations are an angiotensin-converting enzyme (ACE) inhibitor-calcium antagonist combination or a ␤-blocker-calcium antagonist combination. The rationale for an ACE inhibitorcalcium antagonist combination is based on the fact that both drugs reduce vasoconstriction through different mechanisms. The ACE inhibitor largely attenuates vasoconstriction through augmentation of vasodilatory kinins and reduction of the vasoconstrictive effect of angiotensin II, whereas the calcium antagonists, through attenuating the transmembrane flux of calcium, inhibit calcium-mediated electromechanical coupling in contractile tissue in response to numerous stimuli. Moreover, both classes of drugs facilitate salt and water excretion by the kidney through different mechanisms. The ACE inhibitor restores the renal-adrenal response to salt loading, whereas the calcium antagonist possesses intrinsic natriuretic properties through poorly described mechanisms of inhibiting renal tubular salt and water reabsorption. The combination of a ␤-blocker and dihydropyridine calcium antagonist is logical due to the different antihypertensive mechanisms of these drugs without risk of cardiac conduction abnormalities. There is evidence in clinical trials that ACE inhibitors may offset one of the major side effects associated with calcium antagonist therapy: pedal edema. Although the studies are small and the observations subjective, there is consistent evidence that the combination may provide an opportunity to reduce the likelihood of this common clinical problem. There is also evidence of reduced calcium antagonistassociated constipation and headache with this type of drug combination, likely because lower doses of this agent are used in combination with ACE inhibitors. However, there is no published evidence that calcium antagonists reduce the cough associated with the ACE inhibitor. Am J Hypertens 1998;11:163S-169S
A s noted in the Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V), only 21% of the patients with hypertension in the United States can be classified as controlled. 1 As shown in Table 1 , about half of those with hypertension are undergoing therapy, but many are not controlled to a blood pressure of 140/90 mm Hg. The poor control rate is most likely not caused by the use of inadequate drugs, but rather by poor education about the importance of hypertension treatment and side effects related to hypertension.
Hypertension is an asymptomatic disease. Unfortunately, most patients are treated with medical regimens that tend to cause symptoms. Traditional teachings have focused on taking a single-agent and titrating the dose higher to achieve control. Also unfortunately, adverse drug reactions also tend to occur in the same dose-response fashion. It might be more appropriate to design therapeutic combinations of drugs that will work synergistically with one another to improve efficacy and avoid the adverse drug reactions associated with higher doses of the individual monotherapies. Ideally, one therapy would offset the potential adverse events of the other. The development of such regimens will require experimentation and study. Such combinations must address the various factors underlying hypertension in different individuals, including blood volume, vasoconstriction, and the impact of the sympathetic nervous system and the renin-angiotensin system. [2] [3] [4] Recent clinical studies have demonstrated some success at identifying optimal combinations. 5, 6 Strategies to control hypertension are hindered by our incomplete understanding of the exact pathophysiologic mechanisms that result in higher levels of systemic arterial pressure in a given patient. The major hemodynamic abnormality present in most patients with hypertension as they age is an increase in peripheral vascular resistance, 2 and there are many different factors that can contribute to this process. Other factors that can contribute to higher levels of blood pressure include abnormalities of salt and water retention, resulting in greater blood volume, and excessive hyperadrenergic activity may also stimulate excessive cardiac output. [2] [3] [4] How these processes interplay to raise blood pressure in a given patient is not well known. Consequently, a multifaceted approach to the treatment of hypertension makes sense.
Success in controlling blood pressure, and reducing end-organ damage, will not occur unless adequate compliance is achieved with the therapeutic regimen; patients must be able to tolerate the medication for a prolonged period of time. Simplicity, convenience, and minimal side effects are critical to maintaining compliance in these patients. Moreover, clinical experience with most antihypertensive drugs demonstrates efficacy in the 40% to 55% range, whereas two-drug regimens (usually a diuretic with another drug) frequently result in response rates greater than 80%. 7, 8 
DIURETIC-BASED COMBINATIONS
In the 1960s and 1970s, diuretics formed the mainstay of antihypertensive therapy, frequently in combination therapy. In the 1960s, reserpine-hydralazine-hydrochlorothiazide was one of the first commonly used fixed-dose combinations; hydrochlorothiazide was also frequently administered with methyldopa. Thiazides were mixed with many other drugs including potassium-sparing diuretics, spironolactone, ␤-blockers, and with clonidine. 9 In the 1980s, thiazides were mixed with angiotensin-converting enzyme (ACE) inhibitors. In the 1990s, the ␤-blocker and thiazide combination returned, but with lower doses of both moieties. 5, 6 Table 2 illustrates the results of early studies combining thiazide diuretics at doses of 15 mg or less with other antihypertensive agents such as ACE inhibitors, angiotensin II receptor blockers, and ␤-blockers. 9 The majority of combinations result in a greater drop in blood pressure than either drug alone, particularly among the combinations with ACE inhibitors. These combina- tions support the complementary effects of a drug that attenuates the renin-angiotensin system with a drug that facilitates salt and water excretion. More recently, even lower doses of thiazides (6.25 mg) have been combined with other agents to achieve efficacy yet avoid individual adverse events. 5, 6 In one trial, 6.25 mg of hydrochlorothiazide was administered with bisoprolol (cardioselective ␤-blocker). As demonstrated in Figure 1 , the combination of bisoprolol 2.5 mg/HCTZ 6.25 mg provided the same level of diastolic blood pressure reduction as four times as much as the individual components. 5 Two clinical trials have demonstrated the ability of this low-dose thiazide-␤-blocker combination to control blood pressure similarly to titrated doses of an ACE inhibitor or a calcium antagonist. 6, 10 As shown in Figure 2 , the low-dose combination proved equally effective. Not only did the combination provide similar or better efficacy, but also it was better tolerated with a lower number of patient withdrawals.
For the past 2 years, a low-dose thiazide (12.5 mg) and angiotensin II receptor blocker (losartan) combination has been marketed. This has proven to be an effective agent, and comparable in efficacy to other commonly used drugs such as ␤-blockers, ACE inhibitors, or calcium antagonists. [11] [12] [13] It has also been shown to have an excellent tolerability profile with few adverse events.
NONDIURETIC COMBINATIONS
More recently, investigative efforts have been undertaken to explore fixed-dose combinations of drugs that do not include diuretics. The first nondiuretic fixeddose combinations are an ACE inhibitor-calcium antagonist combination 14 or a ␤-blocker-calcium antagonist combination. 15 The rationale for an ACE inhibitor-calcium antagonist combination is based on the fact that both drugs reduce vasoconstriction through different mechanisms ( Table 3 ). The ACE inhibitor largely attenuates vasoconstriction through augmentation of vasodilatory kinins and reduction of the vasoconstrictive effect of angiotensin II, whereas 
FIGURE 2. Mean change in seated diastolic blood pressure (mm Hg) in 323 middle-aged patients with Stage I-II diastolic hypertension (untreated diastolic blood pressure between 95 and114 mm Hg).
the calcium antagonists, through attenuating the transmembrane flux of calcium, inhibit calcium-mediated electromechanical coupling in contractile tissue in response to numerous stimuli. 16, 17 Moreover, both classes of drugs facilitate salt and water excretion by the kidney through different mechanisms. 18, 19 The ACE inhibitor restores the renal-adrenal response to salt loading, 18 whereas the calcium antagonist possesses intrinsic natriuretic properties through poorly described mechanisms of inhibiting renal tubular salt and water reabsorption. 19 The combination of a ␤-blocker and dihydropyridine calcium antagonist is logical due to different antihypertensive mechanisms of these drugs without risk for cardiac conduction abnormalities.
Several clinical trials of various combinations of ACE inhibitors and calcium antagonists have demonstrated that, in general, the antihypertensive efficacy of the components are nearly additive. 20 -25 A benazepril/amlodipine regimen has been extensively studied and was the first approved by the US Food and Drug Administration (FDA). This therapy has demonstrated additive reduction in blood pressure and evidence that each component contributes to the antihypertensive efficacy.
Five protocols have examined the benazepril-amlodipine combination. All five studies employed a similar design, including a 2-week washout period followed by a 2-to 4-week placebo lead-in period. All studies were placebo controlled, comparing the single agents benazepril or amlodipine with the low-dose combination for a period of 8 weeks. Mean sitting systolic and diastolic blood pressures were reduced by various dosages of both agents alone, and by combination therapy (Figures 3, 4) . As can be seen in Figure  3 , the greatest reduction in diastolic blood pressure was observed in patients receiving 20 mg of benazepril and 5 mg of amlodipine, at 13.2 mm Hg. Similar reductions of systolic pressure were also observed, with the combination containing 20 mg of benazepril and 5 mg of amlodipine achieving an average reduction of 24.7 mm Hg (Figure 4) . Overall, approximately half of the patients responded to either amlodipine or benazepril alone, whereas the response to combined therapy was 87%, and supports the enhanced efficacy of the combination, compared with either agent alone.
Based on the model of the benazepril/amlodipine regimen are the enalapril/felodipine combination and a trandolapril/verapamil combination. Both are now approved by the FDA. The enalapril-diltiazem is soon to be marketed. All ACE inhibitor/calcium antagonist combinations offer near-additive antihypertensive properties. 26 -28 The only ␤-blocker/calcium antagonist combination on the horizon is a metoprolol/felodipine combination. 15 The results of clinical trials suggest that some combinations may provide better additivity than others. 14,26 -28 However, the comparability of the study groups, whether they have underlying cardiac or renal disease, as well as variabilities in dietary salt consumption, could be confounding variables in comparing the results of the different combination products in these clinical trials. 
COMBINATION THERAPY IN HYPERTENSION 167S
Interestingly, there is evidence in these clinical trials that ACE inhibitors may offset one of the major side effects associated with calcium antagonist therapy: pedal edema. 14,26 -28 Although the studies are small and the observations subjective, there is consistent evidence that the combination may provide an opportunity to reduce the likelihood of this common clinical problem. There is also evidence of reduced calcium antagonist-associated constipation and headache with this type of drug combination, likely because lower doses of this agent are used in combination with ACE inhibitors. However, there is no published evidence that calcium antagonists reduce the cough associated with the ACE inhibitor.
Of 1135 patients who received the benazepril/amlodipine combination, 49 (4.2%) withdrew prematurely from therapy; this compared with a placebo withdrawal rate of 3.4% in the placebo group. The most common side effect observed during the trials was ankle edema after single-agent therapy with amlodipine; this side effect was most prevalent in women, occurring in 9.1% of those treated. The incidence of this side effect was ameliorated to a great degree by combination therapy. The rate in women fell to 3.2%, whereas the rate in men fell from 2.2% in those taking amlodipine alone to 0.6% in those receiving the combination. This combination would obviate the addition of a diuretic to a calcium antagonist to alleviate the edema, which has become common clinical practice in the United States. This latter practice, no matter how widespread, is ill-advised; calcium antagonists are natriuretic drugs 19 and cause edema predominantly through a capillary leak syndrome, perhaps due to capillary hypertension caused by the significant vasodilation that they cause. ACE inhibitors induce venous capacitance vessel dilation, and may therefore block the capillary leakage and so reduce the amount of associated edema. Diuretics do not attenuate the edema related to calcium antagonists.
The combination of an ACE inhibitor and a calcium antagonist may also be beneficial for amelioration of disease in target organs such as the heart and the kidney (Tables 4, 5 ). For example, the combination of an ACE inhibitor and a calcium antagonist might be more appropriate in a patient with ischemic heart disease, where there may be a need to reduce heart rate, improve diastolic function, and limit ventricular remodeling. Likewise, there is clinical evidence to support the concept that ACE inhibitors and calcium antagonists additively reduce proteinuria and limit the loss of renal function in hypertensive diabetics to a greater extent than either monotherapy alone, independent of blood pressure reduction. 30 In summary, combinations of antihypertensive drugs have been used in clinical practice for decades. In the past, most of these combinations were based on thiazide diuretics as one component of the combination. More recently, efforts have been focused on using lower doses of two agents to achieve the desirable goal of blood pressure reduction, yet avoid the individual toxicities of higher doses of the monotherapies. Some of the potential advantages of a fixed-dose antihypertensive combination approach include the simplicity and convenience of using a single pill. This will be associated with improved compliance and, possibly, enhanced efficacy. Moreover, there may be additional benefits of offsetting undesirable side effects of one component by the other component. There also may be a benefit that the fixed-dose combinations will cost less than the constituents of the combination prescribed separately.
CONCLUSION
The efficacy of the current antihypertensive drugs is adequate, but at increased doses single-agent therapy is associated with side effects that may have an adverse effect on the patient's quality of life, and subsequently undermine compliance. Combining lower doses of antihypertensive agents with complementary mechanisms of action provides efficacy similar to that of higher doses of individual agents, but with a more acceptable side-effect profile. Thus, this approach needs to be considered as an acceptable alternative to the single-drug titration that has been traditionally taught. 
